Welcome to our dedicated page for Unity Biotechnology news (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Biotechnology stock.
Unity Biotechnology, Inc. (NASDAQ: UBX) is a leading biotechnology company focused on developing innovative therapeutics aimed at extending human healthspan by targeting age-related diseases. The company's pioneering approach centers on creating senolytic medicines, which selectively eliminate senescent cells – cells that contribute to aging and various diseases. Unity's initial efforts are directed toward treating conditions such as osteoporosis, eye diseases, and pulmonary diseases.
Unity’s main drug candidates include:
- UBX1325: A promising treatment for age-related eye diseases, including diabetic macular edema (DME). UBX1325 recently demonstrated positive results in the Phase 2 ENVISION study, maintaining vision gains and significantly reducing anti-VEGF treatment needs in patients with wet AMD.
- UBX2089: A circulating hormone being studied for multiple neurological conditions.
- UBX2050: Another investigational drug aimed at age-associated diseases.
Recently, Unity announced the successful results from Part B of the Phase 2 ENVISION study for UBX1325, highlighting its safety and efficacy in maintaining visual acuity and reducing the treatment burden for patients with wet AMD who were not receiving optimal benefits from ongoing anti-VEGF therapy. The study showed that 40% of UBX1325-treated patients did not require anti-VEGF rescue through 48 weeks.
Unity's current focus is on its DME program, where UBX1325 showed a statistically significant improvement in visual acuity during the Phase 2 BEHOLD study. The company has initiated a Phase 2b study and plans to randomize the first patient in Q4 2023. Additional data from the ENVISION study is expected to be presented at upcoming medical conferences.
About the ENVISION Study: The Phase 2 ENVISION study is a multi-center, randomized, double-masked, active-controlled study evaluating the safety, tolerability, efficacy, and durability of UBX1325 in combination with aflibercept for patients with neovascular AMD.
For more detailed information, visit www.unitybiotechnology.com.
UNITY Biotechnology presented 24-week Phase 1 data for UBX1325 at the Angiogenesis, Exudation, and Degeneration 2022 conference. The study involved patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD), showing significant improvements in visual acuity. Key findings include a mean improvement of 9.5 ETDRS letters for DME patients and stabilization in wAMD. UBX1325 was well tolerated, with no significant ocular adverse effects. Phase 2 trials for both conditions are currently underway, with preliminary results expected in mid-2022.
UNITY Biotechnology, Inc. (UBX) announced a strategic restructuring to focus on its ophthalmology clinical programs, particularly the UBX1325 studies, extending its cash runway into Q1 2023. Key data readouts from the Phase 2a study in diabetic macular edema and the Phase 2 study in wet age-related macular degeneration are expected in mid and late 2022, respectively. The workforce will be reduced by approximately 50%, refocusing efforts on more advanced programs to optimize resource allocation.
UNITY Biotechnology, Inc. (NASDAQ: UBX) has announced the grant of a stock-based award covering 2,750 shares to a new employee from January 18 to February 1, 2022. This award, part of the UNITY 2020 Employment Inducement Incentive Plan, aims to incentivize newly hired employees according to Nasdaq rules. UNITY focuses on developing therapeutics to combat age-related diseases by targeting senescent cells, with current efforts in ophthalmologic and neurologic conditions.
UNITY Biotechnology announced the design for its Phase 2 study of UBX1325 targeting wet age-related macular degeneration (AMD) with initial data expected in H2 2022. The study will compare UBX1325 against aflibercept and assess safety and efficacy. Additionally, the company plans to share 12-week safety data from a Phase 2 study in diabetic macular edema (DME) in the first half of 2022. The investigational drug UBX1325 is designed for age-related eye diseases and aims to improve patient outcomes.
UNITY Biotechnology, Inc. (NASDAQ: UBX) announced on December 22, 2021, that its Compensation Committee granted a stock-based award to a new employee from December 7 to December 21, 2021. This award includes options to purchase a total of 4,500 shares of UNITY common stock. The award follows the UNITY 2020 Employment Inducement Incentive Plan, which aims to attract new employees as per Nasdaq Rule 5635(c)(4).
UNITY focuses on developing therapeutics to combat age-related diseases, targeting senescent cells to improve health outcomes in ophthalmologic and neurologic conditions.
UNITY Biotechnology has entered an exclusive licensing agreement with Jocasta Neuroscience for its α-Klotho asset aimed at treating cognitive disorders. This deal enables UNITY to receive an upfront payment and additional milestone payments based on development and sales. The α-Klotho protein has shown promise in preclinical studies for improving cognitive performance, potentially counteracting Alzheimer’s disease symptoms. UNITY will focus on advancing its leading program, UBX1325, while benefiting economically from α-Klotho's development.
UNITY Biotechnology (UBX) reported Q3 2021 financial results, highlighting favorable outcomes from the Phase 1 study of UBX1325, a novel senolytic therapy. The Phase 1 trial demonstrated a favorable safety profile and biological activity over six months. Currently, a Phase 2 study for diabetic macular edema (DME) is enrolling patients, with a second Phase 2 study in age-related macular degeneration (AMD) anticipated in H1 2022. As of September 30, 2021, cash equivalents totaled $88.5 million, sufficient to sustain operations through Q3 2022.
UNITY Biotechnology announced promising results from its Phase 1 trial of UBX1325, targeting diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Patients in higher dose cohorts with DME gained an average of 9.5 ETDRS letters in visual acuity over 24 weeks post-injection. For wet AMD, visual improvements were noted at 12 weeks. The treatment was well-tolerated with no significant side effects. UNITY plans to advance UBX1325 into Phase 2 studies for both conditions in 2022, expecting crucial safety and efficacy data next year.
UNITY Biotechnology, Inc. (NASDAQ: UBX) announced the grant of stock-based awards totaling 190,000 shares from October 19 to November 2, 2021. This includes options for 160,000 shares and 30,000 restricted stock units, which will vest after one year. These grants were made under the amended 2020 Employment Inducement Incentive Plan to incentivize newly hired employees, as per Nasdaq Rule 5635(c)(4). UNITY is focused on developing therapeutics targeting age-related diseases by eliminating senescent cells.
UNITY Biotechnology announced the granting of stock-based awards covering 138,500 shares of common stock to four new employees between September 21 and October 5, 2021. This initiative is part of the 2020 Employment Inducement Incentive Plan, approved by the Board in March 2020, aimed at attracting talent in line with Nasdaq Rule 5635(c)(4). UNITY focuses on developing therapeutics targeting age-related diseases by eliminating senescent cells, particularly in ophthalmologic and neurologic areas.
FAQ
What is the current stock price of Unity Biotechnology (UBX)?
What is the market cap of Unity Biotechnology (UBX)?
What is Unity Biotechnology's primary focus?
What diseases is Unity Biotechnology targeting?
What is UBX1325?
What were the latest results from the ENVISION study?
What are the current projects of Unity Biotechnology?
Where can I find more information about Unity Biotechnology?
What is the significance of senolytic medicines?
Has UBX1325 been approved for use?
What is the expected timeline for the ASPIRE study?
What partnerships does Unity Biotechnology have?
